GCP
BOLD

GSA Capital Partners’s Boundless Bio BOLD Stock Holding History

GSA Capital Partners’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Buy
96,824
+34,348
+55% +$40.2K 0.01% 1560
2025
Q4 		$75K Buy
+62,476
New +$77.9K 0.01% 1554

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

GSA Capital Partners's BOLD Position: Q1 2026 in Review

GSA Capital Partners increased its Boundless Bio (BOLD) stake by 55% in Q1 2026, buying an estimated $40.2K and bringing the position to 96,824 shares worth $107K. The position accounts for 0.01% of the portfolio, ranked #1560.

GSA Capital Partners first reported a position in BOLD in Q4 2025 and has held it in 2 quarters since. 36 funds tracked by Wall St. Rank hold BOLD as of Q1 2026.

  • GSA Capital Partners held 96,824 shares of Boundless Bio worth $107K as of Q1 2026.
  • GSA Capital Partners bought 34,348 Boundless Bio shares in Q1 2026, an estimated $40.2K.
  • Boundless Bio made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1560 holding.
  • GSA Capital Partners first reported a position in Boundless Bio in Q4 2025 and has held it in 2 quarters since.
  • 36 funds tracked by Wall St. Rank held Boundless Bio as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.